Lyophilized Bacterial Compositions for S. Aureus Virulence Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin diseases caused by Staphylococcus aureus are inadequate in effectively suppressing the virulence of the bacteria and reducing associated symptoms.
Innovation Solution
Compositions comprising purified bacterial strains with specific 16s rRNA sequences are formulated for topical application, which are lyophilized and include a combination of bacterial strains that reduce the expression of virulence genes in S. aureus, such as gmk, agr, psma, saeR, and SigB, thereby suppressing bacterial virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for skin diseases caused by S. aureus, then treatment is provided, but the virulence of the bacteria is not effectively suppressed
Solution Approach 1:
The patent uses lyophilized bacterial strains (potential contaminants or commensals) to suppress the virulence of pathogenic S. aureus. The bacterial strains, when applied topically, convert the harmful effect of bacterial presence into a beneficial therapeutic effect by reducing virulence gene expression through competitive interaction and modulation of bacterial behavior.
Solution Approach 2:
The lyophilized bacterial strains act as intermediaries between the skin environment and the pathogenic S. aureus. These strains modulate the bacterial community and directly interact with S. aureus to suppress virulence, serving as a mediator that reduces harmful effects without requiring direct intervention with the pathogen itself.
2Stability of the object's composition
If bacterial strains are lyophilized for stability, then storage stability is improved, but viability may be reduced
Solution Approach 1:
The patent employs lyophilization (freeze-drying) to transition bacterial strains from a liquid state to a solid, stable powder form. This phase transition allows the bacteria to be stored at room temperature with maintained viability, resolving the contradiction between stability and viability by creating a stable solid form that preserves biological activity.
Solution Approach 2:
The lyophilization process provides beforehand cushioning by creating a protective dehydrated state that shields bacterial cells from environmental stressors during storage. This pre-protection ensures that when the product is stored and later applied, the bacteria remain viable and functional despite the harsh storage conditions.
3Reliability
If multiple bacterial strains are combined, then suppression of virulence genes is improved, but composition complexity increases
Solution Approach 1:
The patent combines multiple lyophilized bacterial strains into a single composite formulation that works synergistically to suppress virulence genes. By merging different strains with complementary mechanisms of action, the composition achieves enhanced effectiveness against multiple virulence pathways while maintaining a unified, manageable product form.
Solution Approach 2:
The invention creates a composite bacterial composition where multiple strains are formulated together in a lyophilized matrix. This composite approach allows the different strains to work together synergistically, providing broad-spectrum virulence suppression while the lyophilization process maintains the composite structure stable and easy to handle.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacterial strains effectively suppress the virulence of S. aureus, reducing symptoms of skin conditions such as atopic dermatitis and inflammation, and maintaining stability over time.
Implementation Method 1
The bacterial strains when contacted with S. aureus cause a reduction in expression of at least one of the following genes: gmk, agr, psma, saeR, ccpA, and SigB in S. aureus
Implementation Method 2
wherein the bacterial strains are lyophilized; the composition when stored in a sealed container placed at 20° C. retains at least about: 10^4 cfu after 6 months, as measured by cfu counts
Data Source
AI summary
Provided herein are compositions, methods, kits, and devices for the treatment of skin diseases. Also provided herein are isolated and purified bacteria, excipients, carriers, dosage forms and routes of administration for such bacteria. Furthermore, provided herein are isolated and purified mixtures of bacteria, excipients, carriers, dosage forms and routes of administration for such mixtures. Also provided herein are conditions for treatment with bacteria and bacterial mixtures.